- Home
- MESO
MESO
Mesoblast Limited
as 02-21-2025 4:00pm EST
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
| Founded: | 2004 | Country: | Australia |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.0B | IPO Year: | N/A |
| Target Price: | $18.00 | AVG Volume (30 days): | 252.1K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.91 - $22.00 | Next Earning Date: | 03-04-2025 |
| Revenue: | $5,902,000 | Revenue Growth: | -21.32% |
| Revenue Growth (this year): | 140.44% | Revenue Growth (next year): | 318.31% |
Latest Mesoblast Limited News
MESO Breaking Stock News: Dive into MESO Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
GlobeNewswire
9 days ago
Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings
Simply Wall St.
10 days ago
Domino's Pizza Enterprises And 2 Other ASX Stocks That Might Be Trading Below Fair Value
Insider Monkey
11 days ago
Is Mesoblast Limited (MESO) the Best Long Term ASX Stock to Buy Now?
Simply Wall St.
19 days ago
High Growth Tech Stocks in Australia Featuring FINEOS Corporation Holdings and Two Others
Insider Monkey
22 days ago
Is Mesoblast Limited (MESO) One of the Best ASX Stocks to Buy According to Hedge Funds?
GlobeNewswire
23 days ago
Ryoncil® Commercial Launch Update and Product Pipeline
GlobeNewswire
23 days ago
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024
Compare MESO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MESO Mesoblast Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.